Articles tagged "Post-transplant lymphoproliferative disorder (PTLD)"

2019 American Transplant Congress
Regulation of Host microRNA Expression by Natural Variants of Epstein Barr Virus (EBV) Latent Membrane Protein 1 (LMP1)
O. Hatton¹, A. Harris-Arnold², A. Hui², E. Maloney², S. M. Krams², O. M. Martinez²
¹Molecular Biology, Colorado College, Colorado Springs, CO, ²Program in Immunology and Department of Surgery, Stanford University, Stanford, CA
*Purpose: Malignancies attributable to EBV, such as post-transplant lymphoproliferative disorder (PTLD), represent 1.8% of global cancer deaths. PTLD occurs in 1-20% of transplant recipients and…
2019 American Transplant Congress
Mass Cytometry-Based Characterization of Adaptive Immunity in Transplant Recipients with Self-Limiting or Chronic EBV Viremia
V. H. Ferreira¹, C. J. Guidos², A. Humar¹, D. Kumar¹
¹UHN, Toronto, ON, Canada, ²SickKids Research Inst, Toronto, ON, Canada
*Purpose: SOT recipients are at high risk for EBV-associated PTLD. EBV viremia is a risk factor for PTLD. In some patients viremia is self-limited while…
2019 American Transplant Congress
Ex-Vivo Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus
T. Ku, M. Cypel, R. V. Ribeiro, V. H. Ferreira, D. Kumar, A. Humar
UHN, Toronto, ON, Canada
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) can manifest as a B-cell malignancy associated with Epstein-Barr virus (EBV) infection. Risk of PTLD is greatest in EBV D+/R-…
2019 American Transplant Congress
Phylogenetic Analysis of the Epstein Barr Virus Nuclear Antigen-1 and Associated Correlates among Canadian Transplant Patients
M. Abdulnoor¹, S. Isabel¹, T. Paton¹, N. Khodai-Booran¹, T. Schechter¹, P. Birk², T. Blydt-Hansen³, B. Foster⁴, S. Mital¹, V. Phan⁵, S. Urschel⁶, G. Casallo¹, T. Papaz¹, L. Hamiwka⁷, S. Min¹, U. Allen¹
¹University of Toronto, Toronto, ON, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Montreal, Montreal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷University of Calgary, Calgary, AB, Canada
*Purpose: The effect of the genetic diversity of the Epstein-Barr virus (EBV) on clinical outcomes in the transplant setting is important to study. We examined…
2019 American Transplant Congress
Donor Derived Neoplasia: Will It Be a Risk after Clinical Pig Organ Xenotransplantation?
A. Jagdale¹, H. Iwase¹, E. Klein², D. Cooper¹
¹Surgery, University of Alabama at Birmingham, Birmingham, AL, ²Surgery, University of Pittsburgh, Pittsburgh, PA
*Purpose: The survival of the nonhuman primates with life-supporting pig kidney grafts has increased substantially (to >1 year). As clinical pig organ xenotransplantation draws closer,…
2019 American Transplant Congress
EBV⁺ PTLD Cell Lines Secrete Exosomes Containing microRNAs That Alter Immune Responses
S. Syed, E. Maloney, A. Hui, O. Martinez, S. Krams
Stanford Univ School of Med, Stanford, CA
*Purpose: Exosomes are nanometric (50-150nm) membrane vesicles that are released, into blood and other body fluids, by most cell types. Exosomes, which are generated from…
2019 American Transplant Congress
Steadily Dropping Malignancy Rates after Pediatric Kidney Transplantation Have Now Reversed in the Most Recent Era: A Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS)
V. Dharnidharka¹, C. Cramer², A. Chua³, A. Moudgil⁴, K. Martz⁵, T. Blydt-Hansen⁶, J. Smith⁷, A. Neu, on behalf of the NAPRTCS Investigators⁸
¹Washington University in St. Louis, Saint Louis, MO, ²Mayo Clinic, Rochester, MN, ³Duke University, Durham, NC, ⁴Children's National Medical Center, Washington, DC, ⁵Emmes Corporation, Rockville, MD, ⁶BC Children's Hospital, Vancouver, BC, Canada, ⁷Seattle Children's Hospital, Seattle, WA, ⁸Johns Hopkins University, Baltimore, MD
*Purpose: In general, malignancies are very rare in children, compared to older adults. The NAPRTCS registry has collected data on children receiving kidney transplants in…
2018 American Transplant Congress
Characterization of Viral and Host Cell Genomic Alterations in EBV+ PTLD
Y. Balachandran,¹ M. McPherson,¹ S. Boyd,² C. Esquivel,¹ S. Krams,¹ O. Martinez.¹
¹Abdominal Transplant, Stanford University, Stanford; ²Pathology, Stanford University, Stanford.
Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of organ transplantation characterized by abnormal proliferation of lymphoid cells in the setting of immunosuppression after…
2018 American Transplant Congress
Peptides Encoded by EBV Latent Cycle Proteins Affect NK Cell Reactivity
B. Mbiribindi, C. Romero Moreno, C. Esquivel, O. Martinez, S. Krams.
Department of Surgery, Stanford University School of Medicine, Stanford, CA.
Introduction: Epstein–Barr virus (EBV) infects more than 90% of adults worldwide and is associated with several malignancies, including post-transplant lymphoproliferative disorder (PTLD). Although EBV infection…
2018 American Transplant Congress
Follow-Up and Outcomes of Epstein-Barr Virus Negative Recipients after a Kidney Transplant from an Epstein-Barr Virus Positive Donor
C. Dudreuilh, E. Asgari, R. Hilton.
Departments of Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Introduction: Post-transplant lymphoproliferative disorder (PTLD) is one of the most serious complications of chronic immunosuppression after an organ transplant. One of the major risk factors…